[MET改变的非小细胞肺癌靶向治疗的耐药机制与治疗策略]
[Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of Non-small Cell Lung Cancer with MET Alterations].
作者信息
Li Shuzhan, Zhang Xinwei
机构信息
Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin 300060, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2023 Sep 20;26(9):684-691. doi: 10.3779/j.issn.1009-3419.2023.102.33.
Mesenchymal to epithelial transition factor (MET) gene alterations involve in the proliferation, invasion, and metastasis of non-small cell lung cancer. MET-tyrosine kinase inhibitors (TKIs) have been approved to treat non-small cell lung cancer with MET alterations, and resistance to these TKIs is inevitable. Molecular mechanisms of resistance to MET-TKIs are completely unclear. The review focused on potential mechanisms of MET-TKIs resistance and therapeutics strategies to delay and prevent resistance. .
间充质上皮转化因子（MET）基因改变参与非小细胞肺癌的增殖、侵袭和转移。MET酪氨酸激酶抑制剂（TKIs）已被批准用于治疗具有MET改变的非小细胞肺癌，对这些TKIs产生耐药是不可避免的。对MET-TKIs耐药的分子机制尚完全不清楚。本综述聚焦于MET-TKIs耐药的潜在机制以及延缓和预防耐药的治疗策略。
Zotero 插件